236 related articles for article (PubMed ID: 34122423)
21. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
[TBL] [Abstract][Full Text] [Related]
22. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.
Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B
Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 in solid organ transplant recipients: Dynamics of disease progression and inflammatory markers in ICU and non-ICU admitted patients.
Roberts MB; Izzy S; Tahir Z; Al Jarrah A; Fishman JA; El Khoury J
Transpl Infect Dis; 2020 Oct; 22(5):e13407. PubMed ID: 32654303
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Immune Profiling Reveals CD56
Dutt TS; LaVergne SM; Webb TL; Baxter BA; Stromberg S; McFann K; Berry K; Tipton M; Alnachoukati O; Zier L; Ebel G; Dunn J; Henao-Tamayo M; Ryan EP
J Immunol; 2022 Feb; 208(3):685-696. PubMed ID: 34987111
[TBL] [Abstract][Full Text] [Related]
25. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
[TBL] [Abstract][Full Text] [Related]
26. Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning.
Patterson BK; Guevara-Coto J; Yogendra R; Francisco EB; Long E; Pise A; Rodrigues H; Parikh P; Mora J; Mora-Rodríguez RA
Front Immunol; 2021; 12():700782. PubMed ID: 34262570
[TBL] [Abstract][Full Text] [Related]
27. T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19.
Zenarruzabeitia O; Astarloa-Pando G; Terrén I; Orrantia A; Pérez-Garay R; Seijas-Betolaza I; Nieto-Arana J; Imaz-Ayo N; Pérez-Fernández S; Arana-Arri E; Borrego F
Front Immunol; 2021; 12():655934. PubMed ID: 33777054
[TBL] [Abstract][Full Text] [Related]
28. Reduced Expression of Autophagy Markers and Expansion of Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients.
Tomić S; Đokić J; Stevanović D; Ilić N; Gruden-Movsesijan A; Dinić M; Radojević D; Bekić M; Mitrović N; Tomašević R; Mikić D; Stojanović D; Čolić M
Front Immunol; 2021; 12():614599. PubMed ID: 33692788
[TBL] [Abstract][Full Text] [Related]
29. Persistent cellular immunity to SARS-CoV-2 infection.
Breton G; Mendoza P; Hägglöf T; Oliveira TY; Schaefer-Babajew D; Gaebler C; Turroja M; Hurley A; Caskey M; Nussenzweig MC
J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33533915
[TBL] [Abstract][Full Text] [Related]
30. Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19.
Liu Y; Tan W; Chen H; Zhu Y; Wan L; Jiang K; Guo Y; Tang K; Xie C; Yi H; Kuang Y; Luo Y
BMC Infect Dis; 2021 Jan; 21(1):79. PubMed ID: 33461503
[TBL] [Abstract][Full Text] [Related]
31. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection.
Orologas-Stavrou N; Politou M; Rousakis P; Kostopoulos IV; Ntanasis-Stathopoulos I; Jahaj E; Tsiligkeridou E; Gavriatopoulou M; Kastritis E; Kotanidou A; Dimopoulos MA; Tsitsilonis OE; Terpos E
Viruses; 2020 Dec; 13(1):. PubMed ID: 33375675
[TBL] [Abstract][Full Text] [Related]
32. High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19.
Schub D; Klemis V; Schneitler S; Mihm J; Lepper PM; Wilkens H; Bals R; Eichler H; Gärtner BC; Becker SL; Sester U; Sester M; Schmidt T
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 32937615
[TBL] [Abstract][Full Text] [Related]
33. Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset.
Gutiérrez-Bautista JF; Rodriguez-Nicolas A; Rosales-Castillo A; Jiménez P; Garrido F; Anderson P; Ruiz-Cabello F; López-Ruz MÁ
Front Immunol; 2020; 11():596553. PubMed ID: 33324414
[TBL] [Abstract][Full Text] [Related]
34. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
35. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
Front Immunol; 2021; 12():684014. PubMed ID: 34194438
[TBL] [Abstract][Full Text] [Related]
36. Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients.
Gozzi-Silva SC; Oliveira LM; Alberca RW; Pereira NZ; Yoshikawa FS; Pietrobon AJ; Yendo TM; de Souza Andrade MM; Ramos YAL; Brito CA; Oliveira EA; Beserra DR; Orfali RL; Aoki V; Duarte AJDS; Sato MN
Cells; 2022 Oct; 11(21):. PubMed ID: 36359755
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study.
Kalicińska E; Szymczak D; Zińczuk A; Adamik B; Smiechowicz J; Skalec T; Nowicka-Suszko D; Biernat M; Bogucka-Fedorczuk A; Rybka J; Martuszewski A; Gozdzik W; Simon K; Wróbel T
Cells; 2021 May; 10(6):. PubMed ID: 34071149
[TBL] [Abstract][Full Text] [Related]
38. Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity.
Kulkarni-Munje A; Palkar S; Shrivastava S; Lalwani S; Mishra AC; Arankalle VA
Immun Inflamm Dis; 2021 Jun; 9(2):419-434. PubMed ID: 33452858
[TBL] [Abstract][Full Text] [Related]
39. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
40. Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques.
Hasenkrug KJ; Feldmann F; Myers L; Santiago ML; Guo K; Barrett BS; Mickens KL; Carmody A; Okumura A; Rao D; Collins MM; Messer RJ; Lovaglio J; Shaia C; Rosenke R; van Doremalen N; Clancy C; Saturday G; Hanley P; Smith BJ; Meade-White K; Shupert WL; Hawman DW; Feldmann H
mBio; 2021 Aug; 12(4):e0150321. PubMed ID: 34311582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
